Cargando…
Reactive fibrosis precedes doxorubicin‐induced heart failure through sterile inflammation
AIMS: Doxorubicin (DOX)‐induced heart failure has a poor prognosis, and effective treatments have not been established. Because DOX shows cumulative cardiotoxicity, we hypothesized that minimal cardiac remodelling occurred at the initial stage in activating cardiac fibroblasts. Our aim was to invest...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160475/ https://www.ncbi.nlm.nih.gov/pubmed/31984667 http://dx.doi.org/10.1002/ehf2.12616 |
_version_ | 1783522761366306816 |
---|---|
author | Tanaka, Ryo Umemura, Masanari Narikawa, Masatoshi Hikichi, Mayu Osaw, Kohei Fujita, Takayuki Yokoyama, Utako Ishigami, Tomoaki Tamura, Kouichi Ishikawa, Yoshihiro |
author_facet | Tanaka, Ryo Umemura, Masanari Narikawa, Masatoshi Hikichi, Mayu Osaw, Kohei Fujita, Takayuki Yokoyama, Utako Ishigami, Tomoaki Tamura, Kouichi Ishikawa, Yoshihiro |
author_sort | Tanaka, Ryo |
collection | PubMed |
description | AIMS: Doxorubicin (DOX)‐induced heart failure has a poor prognosis, and effective treatments have not been established. Because DOX shows cumulative cardiotoxicity, we hypothesized that minimal cardiac remodelling occurred at the initial stage in activating cardiac fibroblasts. Our aim was to investigate the initial pathophysiology of DOX‐exposed cardiac fibroblasts and propose prophylaxis. METHODS AND RESULTS: An animal study was performed using a lower dose of DOX (4 mg/kg/week for 3 weeks, i.p.) than a toxic cumulative dose. Histological analysis was performed with terminal deoxynucleotidyl transferase‐mediated dUTP nick‐end labelling assay, picrosirius red staining, and immunohistochemical staining. The mechanism was analysed in vitro with a low dose of DOX, which did not induce cell apoptosis. Microarray analysis was performed. Differentially expressed genes were confirmed by enrichment analysis. Mitochondrial damage was assessed by mitochondrial membrane potential. The production of inflammatory cytokines and fibrosis markers was assessed by western blot, quantitative polymerase chain reaction, and ELISA. A phosphokinase antibody array was performed to detect related signalling pathways. Low‐dose DOX did not induced cell death, and fibrosis was localized to the perivascular area in mice. Microarray analysis suggested that DOX induced genes associated with the innate immune system and inflammatory reactions, resulting in cardiac remodelling. DOX induced mitochondrial damage and increased the expression of interleukin‐1. DOX also promoted the expression of fibrotic markers, such as alpha smooth muscle actin and galectin‐3. These responses were induced through stress‐activated protein kinase/c‐Jun NH2‐terminal kinase signalling. A peroxisome proliferator‐activated receptor (PPARγ) agonist attenuated the expression of fibrotic markers through suppressing stress‐activated protein kinase/c‐Jun NH2‐terminal kinase. Furthermore, this molecule also suppressed DOX‐induced early fibrotic responses in vivo. CONCLUSIONS: Low‐dose DOX provoked reactive fibrosis through sterile inflammation evoked by the damaged mitochondria. |
format | Online Article Text |
id | pubmed-7160475 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71604752020-04-20 Reactive fibrosis precedes doxorubicin‐induced heart failure through sterile inflammation Tanaka, Ryo Umemura, Masanari Narikawa, Masatoshi Hikichi, Mayu Osaw, Kohei Fujita, Takayuki Yokoyama, Utako Ishigami, Tomoaki Tamura, Kouichi Ishikawa, Yoshihiro ESC Heart Fail Original Research Articles AIMS: Doxorubicin (DOX)‐induced heart failure has a poor prognosis, and effective treatments have not been established. Because DOX shows cumulative cardiotoxicity, we hypothesized that minimal cardiac remodelling occurred at the initial stage in activating cardiac fibroblasts. Our aim was to investigate the initial pathophysiology of DOX‐exposed cardiac fibroblasts and propose prophylaxis. METHODS AND RESULTS: An animal study was performed using a lower dose of DOX (4 mg/kg/week for 3 weeks, i.p.) than a toxic cumulative dose. Histological analysis was performed with terminal deoxynucleotidyl transferase‐mediated dUTP nick‐end labelling assay, picrosirius red staining, and immunohistochemical staining. The mechanism was analysed in vitro with a low dose of DOX, which did not induce cell apoptosis. Microarray analysis was performed. Differentially expressed genes were confirmed by enrichment analysis. Mitochondrial damage was assessed by mitochondrial membrane potential. The production of inflammatory cytokines and fibrosis markers was assessed by western blot, quantitative polymerase chain reaction, and ELISA. A phosphokinase antibody array was performed to detect related signalling pathways. Low‐dose DOX did not induced cell death, and fibrosis was localized to the perivascular area in mice. Microarray analysis suggested that DOX induced genes associated with the innate immune system and inflammatory reactions, resulting in cardiac remodelling. DOX induced mitochondrial damage and increased the expression of interleukin‐1. DOX also promoted the expression of fibrotic markers, such as alpha smooth muscle actin and galectin‐3. These responses were induced through stress‐activated protein kinase/c‐Jun NH2‐terminal kinase signalling. A peroxisome proliferator‐activated receptor (PPARγ) agonist attenuated the expression of fibrotic markers through suppressing stress‐activated protein kinase/c‐Jun NH2‐terminal kinase. Furthermore, this molecule also suppressed DOX‐induced early fibrotic responses in vivo. CONCLUSIONS: Low‐dose DOX provoked reactive fibrosis through sterile inflammation evoked by the damaged mitochondria. John Wiley and Sons Inc. 2020-01-27 /pmc/articles/PMC7160475/ /pubmed/31984667 http://dx.doi.org/10.1002/ehf2.12616 Text en © 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Research Articles Tanaka, Ryo Umemura, Masanari Narikawa, Masatoshi Hikichi, Mayu Osaw, Kohei Fujita, Takayuki Yokoyama, Utako Ishigami, Tomoaki Tamura, Kouichi Ishikawa, Yoshihiro Reactive fibrosis precedes doxorubicin‐induced heart failure through sterile inflammation |
title | Reactive fibrosis precedes doxorubicin‐induced heart failure through sterile inflammation |
title_full | Reactive fibrosis precedes doxorubicin‐induced heart failure through sterile inflammation |
title_fullStr | Reactive fibrosis precedes doxorubicin‐induced heart failure through sterile inflammation |
title_full_unstemmed | Reactive fibrosis precedes doxorubicin‐induced heart failure through sterile inflammation |
title_short | Reactive fibrosis precedes doxorubicin‐induced heart failure through sterile inflammation |
title_sort | reactive fibrosis precedes doxorubicin‐induced heart failure through sterile inflammation |
topic | Original Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160475/ https://www.ncbi.nlm.nih.gov/pubmed/31984667 http://dx.doi.org/10.1002/ehf2.12616 |
work_keys_str_mv | AT tanakaryo reactivefibrosisprecedesdoxorubicininducedheartfailurethroughsterileinflammation AT umemuramasanari reactivefibrosisprecedesdoxorubicininducedheartfailurethroughsterileinflammation AT narikawamasatoshi reactivefibrosisprecedesdoxorubicininducedheartfailurethroughsterileinflammation AT hikichimayu reactivefibrosisprecedesdoxorubicininducedheartfailurethroughsterileinflammation AT osawkohei reactivefibrosisprecedesdoxorubicininducedheartfailurethroughsterileinflammation AT fujitatakayuki reactivefibrosisprecedesdoxorubicininducedheartfailurethroughsterileinflammation AT yokoyamautako reactivefibrosisprecedesdoxorubicininducedheartfailurethroughsterileinflammation AT ishigamitomoaki reactivefibrosisprecedesdoxorubicininducedheartfailurethroughsterileinflammation AT tamurakouichi reactivefibrosisprecedesdoxorubicininducedheartfailurethroughsterileinflammation AT ishikawayoshihiro reactivefibrosisprecedesdoxorubicininducedheartfailurethroughsterileinflammation |